Factors associated with the etiological uncertainty of drug reactions: a cross-sectional study in southern Brazil1,2

Dear Editor,

We report a retrospective and cross-sectional study, conducted through the analysis of medical records of hospitalized patients evaluated by the Dermatology Service of Hospital de Clínicas de Porto Alegre, with the clinical or histopathological diagnosis of drug reaction, from January 2011 to January 2019. All drug reaction patterns were included, regardless of whether the causative drug was identified or not. Cases in which the diagnosis of drug reaction (DR) was not fully established (when the condition could also correspond to infectious, autoimmune or non-drug-related reactions) were excluded. The DR that were considered severe were the following: Stevens-Johnson Syndrome (SJS), overlap SJS /Toxic Epidermal Necrolysis (TEN), TEN, Drug-Hypersensitivity Syndrome such as DRESS, Acute generalized exanthematous pustulosis (AGEP), and Erythroderma.1

The frequencies of each demographic and clinical variable were described. The statistical analysis was performed using the SPSS v18.0 program. Nonparametric tests were used to assess continuous variables, as the data distribution was non-linear, according to the Kolmogorov-Smirnov test. The Mann-Whitney U test was used for these variables. For categorical variables, associations were assessed using the Chi-squared test. Multiple logistic regression was performed to assess factors that could or not be associated with a higher probability of etiological diagnosis. A result with p < 0.05 was considered significant.

The study identified 354 patients with drug reactions, with an average of 44.25 new cases per year, an annual incidence of 1.4 cases per 1,000 general admissions. The mean age was 46.08 (± 21.307) and 209 (59%) were women. Most had some type of comorbidity (88.7%; n = 314) (Table 1). There was a higher number of non-severe drug reactions (72.3%; n = 256), with maculopapular exanthema being the most common form (58.9%; n = 212). Most patients did not have systemic findings (72.3%; n = 256) (Table 1).

Most cases of drug reactions occurred during the use of more than one medication (79.7%; n = 282). The medians of the number of drugs used at the time of the skin rash and of the suspected drugs were seven (IQR, 0–27) and three (IQR, 1–16), respectively.

In 66.9% (n = 237) of the cases, it was not possible to identify the causative drug. Carbamazepine was the drug most commonly related to the definitive diagnosis (n = 18; 15.4%); followed by phenytoin (n = 16; 13.7%) and dipyrone (n = 11; 9.4%). The main groups were aromatic anticonvulsants (31.6%; n = 37), followed by antimicrobials (29%; n = 34). Of the antimicrobials, penicillins were the main drug class (n = 13) (Table 2).

There was no statistical difference in relation to age (p = 0.429), sex (p = 0.633), and presence of comorbidities (p = 0.321) between cases with or without a defined etiology (Table 3). Patients whose causative drug was not

---

**Table 1** Characteristics of drug reaction patients - Hospital de Clínicas de Porto Alegre, 2011–2019.

| Characteristic                                      | Value (± SD) |
|----------------------------------------------------|--------------|
| Mean Age (± SD)                                    | 46.08 ± 21.307 |
| Sex, % (n)                                         |              |
| Female                                             | 59 (209)     |
| Male                                               | 41 (145)     |
| Number of medications in median (IQR)              | 7 (1–27)     |
| Number of suspected drugs, median (IQR)            | 3 (1–16)     |
| Medication causing drug reaction identified, %     | 33.3 (117)   |
| Severe drug reaction, % (n)                        |              |
| Overlap SJS/NET                                     | 27.6 (98)    |
| Erythema multiforme                                 | 8.5 (30)     |
| DRESS                                              | 6.5 (23)     |
| AGEP                                               | 11 (39)      |
| Erythroderma                                        | 0.6 (2)      |
| Mild drug reaction, % (n)                           |              |
| Exanthema                                          | 59.9 (212)   |
| Fixed pigmented erythema                           | 4.5 (16)     |
| Photosensitivity                                    | 3.4 (12)     |
| Lichenoid Eruption                                  | 0.3 (1)      |
| SDRIFE                                             | 0.8 (3)      |
| Dysesthesia of hands and feet                      | 0.3 (1)      |
| Acneiform reaction                                 | 0.8 (3)      |
| Small vessel cutaneous                             | 1.1 (4)      |
| vasculitis                                         | 1.1 (4)      |
| Urticaria                                          | 1.1 (4)      |
| Extra-cutaneous involvement, % (n)                 |              |
| Eosinophilia                                       | 27.7 (98)    |
| Liver function alteration                           | 18.1 (64)    |
| Fever                                              | 13.3 (47)    |
| Renal function alteration                           | 11.6 (41)    |
| Pneumonitis                                        | 4 (14)       |
| Lymphadenomegaly                                   | 0.3 (1)      |
| Pancytopenia                                       | 0.3 (1)      |
| Presence of comorbidity, % (n)                     |              |
| SAH                                                | 88.7 (314)   |
| Diabetes mellitus                                  | 33.1 (117)   |
| Ischemic heart disease                             | 14.4 (51)    |
| COPD                                               | 5.6 (20)     |
| Asthma                                             | 4.2 (15)     |
| Neoplasia                                          | 1.7 (6)      |
| HIV                                                | 23.7 (84)    |
| Chronic Kidney Disease                             | 11 (39)      |
| Epilepsy                                           | 7.1 (25)     |
| Psychiatric Disease                                | 4.8 (17)     |
| Heart failure                                      | 4 (17)       |
| Cirrhosis                                          | 2.5 (9)      |
| Stroke                                             | 5.6 (20)     |

SD, Standard Deviation; IQR, Interquartile Range; %, Percentage; n, Number.

---

1 How to cite this article: Oliveira FB, Chiamenti P, Horn RB, Bonamigo RR. Factors associated with the etiological uncertainty of drug reactions: a cross-sectional study in southern Brazil. An Bras Dermatol. 2021;96:508–10.

2 Study conducted at the Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.
The following factors were identified as causative of severe drug reactions: Aromatic Anticonvulsants (median 31.6, IQR 29–34), Antimicrobials (11.1, IQR 8–15), Penicillins (8.5, IQR 4.2–6.2), Sulfamethoxazole-trimethoprim (2.5, IQR 1.7–4.2), Cephalosporins (1.7, IQR 0.8–1.7), Macrodantin (0.8, IQR 0.8–1.7), Hydroxychloroquine (0.8, IQR 0.8–1.7), Allopurinol (1.7, IQR 1.7–3.1), Clopidoogrel (0.8, IQR 0.8–1.7), Aspirin (0.8, IQR 0.8–4.1), and Valproic acid (0.8, IQR 0.8–4.1). The total number of drugs identified was 100 (17.2% of the population).

It was already suspected that the use of multiple drugs is an important contributing factor for the impossibility of an etiological diagnosis in drug reactions, which is corroborated by our results.1-4 It is known that multiple drug use is one of the main obstacles in defining the causative drug. In our sample, 79.7% of patients used more than one drug at the time of the skin rash and, consequently, had more than one suspected drug. This showed to be similar to the study by Beniwal et al. which demonstrated that 74% of patients were using multiple drugs at the time of the drug reaction.2

Most of the evaluated patients did not have the causative drug identified, corresponding to 66.9% (n = 237) of the cases. This was related to the high percentage of multiple drug use, 79.7% (n = 282) and a higher median of drugs in use than those described in other studies. The median number of drugs used by the patients in our study was seven (IQR 0–27) and the mean number of suspected drugs was three (IQR 1–16). These numbers are higher than those of other studies, such as the one by Beniwal et al., which was 2.09 (IQR 1–6) and that of Thakkar et al., which observed a mean number of 1.52 (± 0.80).2,3

There are few studies in the literature describing cases in which an etiological diagnosis was not established, since the absence of a diagnosis of the precipitating drug is an exclusion criterion in most protocols. In the case of the study by Zhao J et al.,4 the causative drug was not established in only 13% of patients, who were using more than one medication. However, cases that did not have defined causal drugs or did not have suspected drugs, and if patients were using more than five drugs, were excluded at the selection phase.4 This is in contrast with our study, considering that the median number of drugs in use was higher than five.

In conclusion, in a tertiary referral hospital in southern Brazil, drug reactions are frequent, and the possibility of not having a defined etiology is high. Multiple drugs use is the main factor associated with the etiological ambiguity of drug reactions.

### Financial support

FUNADERM - Fundo de Apoio à Dermatologia, Sociedade Brasileira de Dermatologia, Rio de Janeiro, RJ, Brazil.

### Authors’ contributions

Fabiana Bazanella de Oliveira: Statistical analysis; approval of the final version of the manuscript; design and planning of the study; drafting and editing of the manuscript; collection, analysis, and interpretation of data; effective participation in research orientation; intellectual participation in the propaganda and/or therapeutic conduct of the studied cases; critical review of the literature; critical review of the manuscript.

Paula Chiamenti: Collection, analysis, and interpretation of data.

Roberta de Freitas Horn: Collection, analysis, and interpretation of data.

Renan Rangel Bonamigo: Approval of the final version of the manuscript; design and planning of the study; effective participation in research orientation; intellectual partici-
Table 3  Profile of patients with etiologically defined and undefined drug reactions.

| Comorbidities | Drug reactions with defined etiology | Drug reactions with undefined etiology | p    |
|---------------|--------------------------------------|----------------------------------------|------|
| Age (± SD)    | 40.49 (±22.069)                      | 46.86 (±20.924)                        | 0.429ß |
| Sex, % (n)    |                                      |                                        |      |
| Female        | 32.1 (67)                            | 67.9 (142)                             | 0.633ε |
| Male          | 34.5 (50)                            | 65.5 (95)                              |      |
| Number of medications in use at the time of the skin rash, median (IQR) | 4 (0-26) | 8 (0-27) | < 0.000δ |
| Number of suspected medications, median (IQR) | 1 (1-7) | 3 (1-16) | < 0.000δ |
| Severe drug reactionα | 36.8 (43) | 23.2 (55) | 0.007ε |
| Mild drug reaction | 63.2 (74) | 76.8 (182) | 0.007ε |
| Comorbidities  |                                      |                                        |      |
| Yes           | 32.2 (101)                           | 67.8 (213)                             | 0.321ε |
| No            | 40 (16)                              | 60 (24)                                |      |

α Severe pharmacoderma: DRESS, Overlap SJS/NET, AGEP, Erythroderma, Erythema Multiforme. 
ß Mann-Whitney U test. 
ε Chi-squared.

pation in the propaedeutic and/or therapeutic conduct of studied cases; critical review of the manuscript.

Conflicts of interest

None declared.

References

1. Drake LA, Dinehart SM, Farmer ER, Goltz RW, Graham GF, Hordinsky MK, et al. Guidelines of care for cutaneous adverse drug reactions. American Academy of Dermatology. J Am Acad Dermatol. 1996;35 3 Pt:1-458-61.
2. Beniwal R, Gupta AK, Khare AK, Mittal A, Mehta S, Balai M. Clinical Profile and Comparison of Causality Assessment Tools in Cutaneous Adverse Drug Reactions. Indian Dermatol Online J. 2019;10:27-33.
3. Thakkar S, Patel TK, Vahora R, Bhabhor P, Patel R. Cutaneous adverse drug reactions in a tertiary care teaching hospital in India: An intensive monitoring study. Indian J Dermatol. 2017;62:618-25.
4. Zhao J, Hu L, Zhang L, Zhou M, Gao L, Cheng L. Causative drugs for drug-induced cutaneous reactions in central China: a 608-case analysis. An Bras Dermatol. 2019;94:664-70.

Fabiana Bazanella de Oliveira a,b,*, Paula Chiamenti d,*, Roberta de Freitas Horn d,*, Renan Rangel Bonamigo d,∗

a Universidade Federal de Ciências da Saúde, Porto Alegre, RS, Brazil
b Faculty of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
c Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil

*Corresponding author. 
E-mail address: fabibazanella@gmail.com (F.B. Oliveira).

Received 27 February 2020; accepted 18 August 2020
Available online 27 May 2021

https://doi.org/10.1016/j.abd.2021.04.002
0365-0596/ © 2021 Published by Elsevier España, S.L.U. on behalf of Sociedade Brasileira de Dermatologia. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Leprosy cases diagnosed by contacts examination in a hyperendemic capital city of northeastern Brazil a,b,∗∗

Dear Editor,

Leprosy, an infectious disease with a prolonged incubation period, has in the household contacts an important means for the maintenance of the endemity. It is characterized by a clinical dermatological-neurological syndrome with a high potential to cause physical disabilities and deformities, in addition to social and psychological impacts.1,2

It is still considered a relevant public health problem in most Brazilian states, despite efforts by the Ministry of Health to control the infection.1 In 2018, 208,619 new cases were reported worldwide, with Brazil being the 2nd country with the highest prevalence of the disease, registering a total of 28,660 new cases, representing 13.3% of the global total of new occurrences.3

Household contacts are highly vulnerable to disease development due to prolonged exposure to the bacilli in the home environment. This risk is approximately five to ten times greater in families with one case of the disease and

How to cite this article: Soares AMM, Corrêa RGCF, Santos KCB, Figueiredo IA, Paiva MFL, Aquino DMC. Leprosy cases diagnosed by contacts examination in a hyperendemic capital city of northeastern Brazil. An Bras Dermatol. 2021;96:510-3.

Study conducted at the Universidade Federal do Maranhão, São Luís, Maranhão, MA, Brazil.